Mindestbestellung 120 EUR Kostenlose Lieferung ab 250 EUR Bereit zur Abholung dead drop: in 5 Min. abholen Kostenloser Versand ab 250 EUR Aktionen

Substanzen · Benzodiazepine und Thienodiazepine

Flubromazepam

C15H10BrFN2O CAS 2647-50-9 Nur für analytische Forschungszwecke — nicht für den menschlichen Verzehr
Bevorzugter Name
Flubromazepam
IUPAC-Name
7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
CAS-Nummer der Stammverbindung (Referenz)
2647-50-9
Summenformel
C15H10BrFN2O
Molekulargewicht
333.15 g/mol
InChIKey
ZRKDDZBVSZLOFS-UHFFFAOYSA-N
PubChem
CID 12947024
Quelle
PubChem
Geprüfte Synonyme und Katalogkürzel
Ro 05-2904 7-Bromo-2'-fluorodesmethyldiazepam

Passende Artikel im aktuellen Shop-Katalog

Geprüftes Pharmakologie- & Toxikologie-Dossier

Flubromazepam

Ultra-Long Half-Life GABA-A PAM 1,4-Benzodiazepine
Geprüfte PubChem- & CAS-Identität C15H10BrFN2O · CAS 2647-50-9 · CID 12947024
Kalibrierte Lieferform Präzisionstabletten · 1 Tablette = 1 mg
≥98 % analytische Reinheit geprüft 333.15 g/mol
WHO-, PubMed- & PubChem-Quellen 2 cited records

Rezeptor-Telemetrie & Wirkmechanismus

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Very High
GABAₐ α₅ Amnestic / Cognitive Modulation High

7-Bromo-2'-fluoro-1,4-benzodiazepin-2-one acting as a classic full GABA-A PAM with an elimination half-life exceeding 100 hours in human pharmacokinetic studies.

Biotransformation & Active Metabolites

Human pharmacokinetic study (Moosmann et al.) documents a ~106-hour terminal half-life via monohydroxylated metabolites.

Zeitliche Pharmakokinetik

Ultra-Long Half-Life GABA-A PAM — Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

  1. Onset 45–120 min
  2. Peak Window 3–6 h
  3. Total Window 12–24 h
  4. Residual / Half-Life 36–72+ h residual (T1/2 ~106 h)

Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

Quantitatives Wirkungsspektrum (Literaturdaten)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
2 mg
Cognitive & Sensory

Subtle threshold receptor activity (Ultra-Long Half-Life GABA-A PAM).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
2–4 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
4–8 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
8–12 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
14+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Wechselwirkungsmatrix — Niemals kombinieren

Lebensgefahr — Niemals kombinieren

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Hohes Risiko — Vermeiden

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Vorsicht / Abschwächung

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Isomeren- & Strukturvergleich

Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

Stabilität & Lagerung

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Analytische & toxikologische Monographie

Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one; CAS 2647-50-9, PubChem CID 12947024) is a 1,4-benzodiazepine reference compound (C15H10BrFN2O, 333.15 g/mol) classified pharmacologically as a Ultra-Long Half-Life GABA-A PAM. 7-Bromo-2'-fluoro-1,4-benzodiazepin-2-one acting as a classic full GABA-A PAM with an elimination half-life exceeding 100 hours in human pharmacokinetic studies. Human pharmacokinetic study (Moosmann et al.) documents a ~106-hour terminal half-life via monohydroxylated metabolites. In published observational and toxicological literature, threshold response is noted at 2 mg, light range at 2–4 mg, common reference range at 4–8 mg, strong intensity at 8–12 mg, and heavy/adverse territory at 14+ mg, with an onset of 45–120 min, peak window of 3–6 h, and total duration of 12–24 h (36–72+ h residual (T1/2 ~106 h)). Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemische Struktur und Molekülprofil

Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) ist eine Referenzverbindung aus der Stoffklasse Benzodiazepine und Thienodiazepine mit der Summenformel C15H10BrFN2O und einer molaren Masse von 333.15 g/mol. Die Stammverbindung wird unter der CAS-Nummer 2647-50-9 sowie in der NCBI-PubChem-Datenbank unter CID 12947024 geführt (Standard-InChIKey: ZRKDDZBVSZLOFS-UHFFFAOYSA-N).

Quellen

Referenztoxikologie und Sicherheitsprofil

Laut dokumentierten Referenzdaten (PubChem / PsychonautWiki, CC BY 4.0) gehört Flubromazepam zur chemischen Klasse Benzodiazepines. Toxikologische Hinweise (PsychonautWiki): geringe Eigen-Toxizität; Kombinationen mit Depressiva (Alkohol, Opioide) sind lebensgefährlich. Abhängigkeitspotenzial (PsychonautWiki): sehr hohes physisches und psychisches Abhängigkeitspotenzial. Dokumentierte Kreuztoleranz: benzodiazepines. Beim Umgang im Labor sind geeignete persönliche Schutzausrüstung und das Sicherheitsdatenblatt (SDB) zu beachten.

Quellen

Analytischer Verwendungszweck und Laborhinweis

Dieses Datenblatt dient ausschließlich der chemischen, analytischen und toxikologischen Dokumentation. Das Material ist nicht für den menschlichen Verzehr bestimmt. Ein Forschungshinweis begründet keinen Rechtsstatus.

Quellen